id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-325936-rwxg187r	Eyal, Nir	AIDS Activism and Coronavirus Vaccine Challenge Trials	2020-06-26		.txt	text/plain	2220	115	51	To minimize risk to participants, live SARS-CoV-2 vaccine challenge trials would need to recruit participants who, in the-likely-event of infection, would remain at relatively low fatality risk. Shortly after HIV sterilizing cure trials transplanted allogenic stem cell in participants, with well over a thousand times the fatal risk of SARS-Cov-2 infection in healthy young participants [17, 18] , AIDS activist David Evans interviewed the participants of these risky trials and concluded, "We should recognize their great capacity to understand the risks they may confront as research participants and, after a careful ethical and scientific review, respect the motivations of those who decide that the benefits of knowing that their contributions may help others outweighs the risks" [19] . That is not the case for COVID-19, which means that adequately communicating about and assessing potential risks and benefits of participating in a challenge study and ensuring appropriate informed consent may be impossible.	./cache/cord-325936-rwxg187r.txt	./txt/cord-325936-rwxg187r.txt